In a report released today, Ritu Baral from Cowen & Co. maintained a Buy rating on Intercept Pharma (NASDAQ: ICPT), with a price target of $88. The company’s shares opened today at $72.
According to TipRanks.com, Baral is a top 25 analyst with an average return of 34.3% and a 55.9% success rate. Baral covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, ACADIA Pharmaceuticals Inc, and Allena Pharmaceuticals Inc.
Currently, the analyst consensus on Intercept Pharma is Moderate Buy and the average price target is $107.33, representing a 49.1% upside.
In a report issued on April 27, Wedbush also maintained a Buy rating on the stock with a $203 price target.
See today’s analyst top recommended stocks >>
Based on Intercept Pharma’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $81.59 million. In comparison, last year the company had a GAAP net loss of $89.93 million.
Based on the recent corporate insider activity of 55 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ICPT in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Intercept Pharmaceuticals is a biopharmaceutical company, which engages in the research, development, and commercialization of novel therapeutics in treating chronic liver diseases. Its product pipeline is OCALIVA which is used for the treatment of primary biliary cholangitis, nonalcoholic steatohepatitis, primary sclerosing cholangitis, and biliary atresia.